A Molecular Diagnostics Company
Making Early Cancer Detection the New Standard of Primary Care
Our Mission
For heart disease, thyroid function and diabetes… frequent, recurrent, sequential monitoring and screening are standard of primary care in asymptomatic populations.
Our Science
Find out how we’re unlocking frequent, recurring monitoring for early cancer signal as the new standard of primary care.
More accurate & reliable
More cost effective
fully scalable
significant societal impact
Our Social Impact
Latest News
Acuamark on LinkedIn
August 8, 2024
In a recent discussion on diagnostic company funding, Acuamark CEO Bernard Peperstraete highlighted advances in blood-based diagnostics technologies.
While the industry has a lot to be proud of, especially with respect to late-stage disease detection, Acuamark has engineered the first-ever qPCR-based approach optimized for highly accurate early cancer signal detection at ultra-low abundance.
ENMEDIA: Dx Companies On the Rise
October 16, 2023
AcuamarkDx is pleased to be featured as a diagnostics company on the rise in the premiere issue of ENMEDIA magazine.
Click the link below for the full story.
ENMEDIA Explores Podcast Liquid Biopsy: What’s next?
June 30, 2023
Dr. Giulia Kennedy and Dr. Bernard Peperstraete talk with ENMEDIA about AcuamarkDx's solution to crack early cancer detection – a potential game changer for the liquid biopsy market.
